Table 2.

Multivariate analyses of covariables for overall survival, relapse mortality, and non-relapse mortality

Covariables	OS		CIR		NRM
	Cox proportional hazards		Fine + Gray		Fine + Gray
	HR (95%CI)	P	HR (95%CI)	P	HR (95%CI)	P
Age (per 1 year)	1.02 (1.00–1.03)	0.018	1.00 (0.99–1.02)	0.810	1.02 (1.00–1.04)	0.079
Sex
Male	Ref		Ref		Ref	Ref
Female	0.93 (0.61–1.41)	0.719	0.89 (0.45–1.75)	0.740	1.00 (0.61–1.64)	0.990
Body length (per 1 cm)	1.00 (0.98–1.02)	0.936	1.01 (0.98–1.05)	0.470	0.99 (0.96–1.02)	0.500
AML type
De novo AML	Ref		Ref		Ref
t AML	0.88 (0.41–1.93)	0.756	0.45 (0.11–1.90)	0.280	1.44 (0,62–3.36)	0.390
s AML	0.92 (0.62–1.36)	0.669	0.41 (0.20–0.84)	0.015	1.56 (0.98–2.49)	0.064
HLA match
Matched	Ref		Ref		Ref
Mismatched	0.63 (0.43–0.94)	0.022	0.92 (0.51–1.68)	0.790	0.70 (0.43–1.12)	0.140
Donor relation
Related	Ref		Ref		Ref
Unrelated	0.71 (0.49–1.04)	0.076	0.38 (0.21–0.70)	0.002	1.52 (0.74–1.80)	0.530
Remission status
CR	Ref		Ref		Ref
Active disease	1.50 (1.09–2.07)	0.013	0.95 (0.59–1.52)	0.820	1.99 (1.31–3.01)	0.001
CMV risk
Low	Ref		Ref		Ref
High	1.35 (0.96–1.88)	0.081	1.35 (0.82–2.23)	0.240	1.19 (0.77–1.83)	0.430
Spleen volume
≤ 238.0 cm3	Ref		Ref		Ref
> 238.0 cm3	1.55 (1.12–2.14)	0.008	1.05 (0.66–1.69)	0.830	1.55 (1.03–2.34)	0.035

OS, overall survival; CIR, cumulative incidence of relapse; NRM, non-relapse mortality; Ref, reference; HR, hazard ratio; CI, confidence interval; AML, acute myeloid leukemia; t AML, therapy-associated AML; s AML, secondary AML; HLA, human leukocyte antigen; CR, complete remission; CMV, cytomegalovirus. Low CMV risk, recipient − / donor − or recipient − /donor + ; high CMV risk, recipient + / donor − or recipient + / donor +